BioMedNewsBreaks Archive - BioMedWire (BMW)

FridayNov 14, 2025 9:10 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Reports Q3 2025 Results as FDA Review Nears Completion and Commercial Readiness Accelerates

HeartBeam (NASDAQ: BEAT) reported third-quarter 2025 results and highlighted continued progress toward commercialization of its 12-lead ECG synthesis software, now in the final stage of FDA 510(k) review with anticipated clearance by year end. The company is advancing commercial readiness, including a new partnership with HeartNexus for 24/7 cardiologist review services, alongside new scientific data presented at AHA Scientific Sessions and HRX Live 2025 and an expanded global IP portfolio of 24 issued patents. For the quarter, R&D expenses were $3.3 million, G&A expenses were $2.0 million, net loss was $5.3 million and cash totaled $1.9 million. HeartBeam will discuss…

ThursdayNov 13, 2025 1:08 pm

BioMedNewsBreaks — NextPlat Corp. (NASDAQ: NXPL, NXPLW) Reports Q3 2025 Results Highlighted by Cost Reductions and Improving Healthcare Trends

NextPlat (NASDAQ: NXPL, NXPLW) reported third-quarter 2025 results showing consolidated revenue of about $13.8 million compared with $15.4 million in the prior year, primarily reflecting lower 340B pharmacy contract revenue before late-quarter customer re-engagement efforts drove improving prescription volumes expected to continue into Q4. Gross margin declined to 19.9% from 23.2% on lower Healthcare and e-commerce margins tied to reduced 340B revenue, new airtime costs and temporary customer rate adjustments. Operating expenses fell to roughly $4.7 million from $7.8 million as stock-based compensation, executive compensation and headcount decreased under companywide efficiency measures, contributing to a reduced net loss of about…

ThursdayNov 13, 2025 10:30 am

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Q3 2025 Results and Highlights AI-Driven Clinical Progress

Lantern Pharma (NASDAQ: LTRN) reported third-quarter 2025 results and advanced multiple AI-driven oncology programs, highlighted by completion of enrollment and achievement of all primary endpoints in the LP-184 Phase 1a trial, which showed a 48% clinical benefit rate at or above the therapeutic dose threshold along with a favorable safety profile and strong biomarker correlations. The company also outlined plans for Phase 1b/2 studies in TNBC, NSCLC with STK11/KEAP1 co-mutations, and bladder cancer, supported by pharmacokinetic data establishing a recommended Phase 2 dose of 0.39 mg/kg. Lantern noted catalyst-rich progress across its pipeline, including regulatory clarity for its pediatric CNS…

WednesdayNov 12, 2025 12:39 pm

BioMedNewsBreaks — Astiva Health Earns 2026 Senior Choice Gold Award for Excellence in Medicare Advantage Performance and Value

Astiva Health, a rapidly growing Medicare Advantage organization serving California’s diverse senior population, has been awarded the 2026 Senior Choice Gold Award by HealthMetrix Research Inc., recognizing its superior cost-effective coverage and culturally aligned care model. With a 4-star CMS quality rating and more than 38,000 members across the state, Astiva continues to lead in delivering high-value, community-based healthcare—particularly among underserved and multilingual populations in San Diego and Santa Clara. “This recognition reflects our commitment to not only serve, but to understand and elevate the communities we care for,” said Dr. Tri T. Nguyen, co-founder and CEO. To view the…

WednesdayNov 12, 2025 11:55 am

BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Q3 2025 Financial Results and Host Conference Call on Nov. 17

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced it will release its third quarter 2025 financial results before market open on Monday, Nov. 17, 2025, followed by a conference call at 8:30 a.m. ET to discuss corporate, financial, and operational updates. To view the full press release, visit https://ibn.fm/RNyEd About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been…

TuesdayNov 11, 2025 10:45 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Sapu Bioscience Publish Landmark Review Defining Sub-15 nm Nanoparticles as New Frontier in Drug Delivery

Oncotelic Therapeutics (OTCQB: OTLC), and joint venture partner Sapu Bioscience today announced the publication of their review article, “Sub-15 nm Nanoparticles for Drug Delivery: Emerging Frontiers and Therapeutic Potential,” in the International Journal of Molecular Sciences (IJMS 2025, 26, 10842; https://doi.org/10.3390/ijms262210842). Authored by Dr. Tapas De, Vuong Trieu, Scott Myers, Sanjive Qazi, Saran Saund, and Cynthia Lee, the paper is the first to comprehensively examine nanoparticles exclusively within the 5–15 nm range—an emerging scale poised to redefine nanomedicine. The review highlights how these sub-15 nm systems achieve deeper tissue penetration, reduced organ accumulation, faster renal clearance, and enhanced diffusion across…

MondayNov 10, 2025 3:11 pm

BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Launches HOPE Therapeutics’ One-Day TMS Protocol for Treatment-Resistant Depression in Florida

NRx Pharmaceuticals (NASDAQ: NRXP), announced that its subsidiary, HOPE Therapeutics(TM), has initiated patient care using the Ampa “one day” (ONE-D) protocol for treatment-resistant depression—the first deployment of its kind in Florida and among the first nationwide. The Ampa device combines a single day of transcranial magnetic stimulation (TMS) with physician-prescribed D-cycloserine and lisdexamfetamine, which in peer-reviewed studies have shown response rates of 87% and remission rates of 72% in nonrandomized trials. Under the direction of Medical Director Dr. Rebecca Cohen, HOPE clinics in Sarasota, Naples, and Fort Myers are now offering the protocol, with six Florida locations expected by year-end.…

MondayNov 10, 2025 12:16 pm

BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) CEO Discusses AI-Driven Cancer Drug Development in FintechTV Interview at NYSE

• Lantern’s AI platform “learns, reads, models, and predicts” to identify new drugs and indications • CEO Panna Sharma says AI is compressing development timelines and cost structures across oncology Lantern Pharma (NASDAQ: LTRN), an AI-driven cancer drug developer, is using large-scale machine learning to discover new therapies, reposition existing molecules, and target high-unmet-need oncology indications. CEO Panna Sharma told FintechTV the company’s proprietary platform now self-learns, reads scientific papers, models molecules, predicts patient response, and suggests new indications — significantly reducing the time and cost of drug development. Lantern has three clinical-stage oncology candidates, including a Phase 2 trial for…

FridayNov 07, 2025 3:29 pm

BioMedNewsBreaks — Oncotelic Therapeutics Inc. (OTLC) Venture Begins Clinical Trials of Innovative Cancer Therapy

Oncotelic Therapeutics (OTCQB: OTLC) venture Sapu Nano recently secured approval from Australia’s Human Research Ethics Committee (“HREC”) to begin enrolling patients in clinical trials for Sapu003, an injectible form of Afinitor(R) (everolimus) for breast cancer treatment. Using Sapu Nano’s proprietary Deciparticle(TM) technology, Sapu003 delivers Everolimus directly into the bloodstream. “The approval of Sapu003 to enter human trials is a landmark moment. By enabling full drug absorption through intravenous delivery, this program has the potential to achieve meaningful tumor shrinkage where oral formulations have been limited,” said Dr. Sud Agarwal, CEO of Ingenu, a contract research organization in Australia. “We are proud…

FridayNov 07, 2025 10:05 am

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Highlights Key Clinical Progress and Reports Q3 2025 Financial Results

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company advancing treatments for rare diseases with unmet medical need, reported third quarter 2025 results and outlined upcoming milestones, including top-line Phase 2a results for SGX302 in psoriasis and an enrollment update for its confirmatory Phase 3 HyBryte(TM) study in cutaneous T-cell lymphoma (CTCL). CEO Christopher J. Schaber, PhD, confirmed that the first Data Monitoring Committee review found no safety concerns for HyBryte(TM), maintaining a consistent safety profile across trials. With $10.5 million in cash as of Sept. 30, 2025, Soligenix expects its operating runway to extend through 2026 while evaluating strategic options to…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Reports Q3 2025 Results as FDA Review Nears Completion and Commercial Readiness Accelerates

BioMedNewsBreaks — NextPlat Corp. (NASDAQ: NXPL, NXPLW) Reports Q3 2025 Results Highlighted by Cost Reductions and Improving Healthcare Trends

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Q3 2025 Results and Highlights AI-Driven Clinical Progress

BioMedNewsBreaks — Astiva Health Earns 2026 Senior Choice Gold Award for Excellence in Medicare Advantage Performance and Value

BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Q3 2025 Financial Results and Host Conference Call on Nov. 17

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Sapu Bioscience Publish Landmark Review Defining Sub-15 nm Nanoparticles as New Frontier in Drug Delivery

BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Launches HOPE Therapeutics’ One-Day TMS Protocol for Treatment-Resistant Depression in Florida

BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) CEO Discusses AI-Driven Cancer Drug Development in FintechTV Interview at NYSE

BioMedNewsBreaks — Oncotelic Therapeutics Inc. (OTLC) Venture Begins Clinical Trials of Innovative Cancer Therapy

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Highlights Key Clinical Progress and Reports Q3 2025 Financial Results

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search